

U.S. Application No.: 10/534,590
Amendment to Non-Final Office Action
dated July 6, 2008

Attorney Docket No. 69112(303198)

AMENDMENTS TO THE DRAWINGS

The attached corrected drawings include changes to Figures 1, 3a, 4, 5, 12 and 13, in which the figures are amended to be legible. No new matter is added.

Attachment: Replacement Sheets

REMARKS

Claims 1 and 2 have been amended to change the term "BMP-7" polypeptide to "mature BMP-7" polypeptide. The abstract of the disclosure has been amended to correct informalities. Figs 1, 3a, 4, 5, 12 and 13 have been amended so as to be legible. No new matter has been added.

The SEQ ID NO: 1 has been amended to list the sequence of mature BMP-7. It was known before the priority date of the present application that biologically active form is mature BMP-7. The sequence of mature BMP-7 was also known. Applicant intended to list the sequence of mature BMP-7, rather than the currently listed sequence, in SEQ ID NO:1. The amendment has been made to correct this error. No new matter has been amended. In this regards, written sequence listing and computer readable form copy thereof are submitted herewith. Also, statements pursuant to 37 CFR 1.821(f)&(d) is concurrently submitted.

To correct the defective declaration, a new declaration signed and dated by the inventors is submitted herewith.

The drawings and the specification were objected to for informalities. The objections should be withdrawn by the amendments.

Claims 1-4 were rejected as violating enablement requirement. As the Office Action (page 4) acknowledged, the specification enables a composition for inhibiting a scar formation comprising an effective amount of a 'mature' BMP-7 protein. To comply with the enablement requirement, claim 1 has been amended to correct the term "BMP-7" to "**mature BMP-7.**" Also, SEQ ID NO: 1 has been amended as described above. Thus, the rejections should be withdrawn.

For at least the foregoing reasons, it is believed that the claims are in condition for allowance, which action is earnestly solicited.

U.S. Application No.: 10/534,590
Amendment to Non-Final Office Action
dated July 6, 2008

Attorney Docket No. 69112(303198)

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 69112(303198).

Respectfully submitted,

Date: July 6, 2008

/Kongsik Kim/

Kongsik Kim
(Reg. No. L0364)

Edwards Angell Palmer & Dodge LLP
P.O. Box 55874
Boston, MA 02205
(Tel) 617-239-0100
Attorneys/Agents For Applicants